The patents on Remicade and Humira are expiring soon, which means other companies can make the drugs since it's a generic drug soon.
Remicade and Humira are the brand names, the name of the drugs are Inflixmab and Adalimumab, the patents on the drugs will expire.
It's likely targeted at crohn's disease because for RA there are many more choices in biologics.
That's also the reason those companies behind those drugs started vedolizumab, because infliximab and humira are a billion dollar business and the companies behind those do not want to see that billion dollar cash cow go down the drain when the patents expire.
But vedolizumab hasn't been a success, in many studies it's hardly better than a placebo.
Vedolizumab was meant to replace the cash cow, it was supposed to be safer and more effective. But it was neither, a few hospitals refused to do trials with it after a few deaths occured (it was named something else before), the formula was changed, but the new formula is apparently safer but it's really ineffective, it hardly wins against placebo.
Which is why those same companies are promoting humira again, since vedolizumab basically failed.